Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Patients With Metastatic Hormone Reseptor Positive Breast Cancer

NCT03409198 is registered in ClinicalTrials.gov with Oslo University Hospital as lead sponsor.

NCT NCT03409198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03409198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Patients With Metastatic Hormone Reseptor Positive Breast Cancer
Lead sponsor
Oslo University Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 21, 2018
Completion date
May 11, 2022
Enrollment
82 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hormone receptor positive tumor, metastatic breast cancer